

PEPFAR's Latest Global Results

2022



Through the reduction of incidence and prevalence of HIV among adolescent girls and young women, women of child-bearing age, and adult men, an additional 3.5 million babies were born HIV-free from 2004 to 2021. Now, 5.5 million babies have been born HIV-free as a result of PEPFAR and its partners.

5.5 million babies born HIV-free

Through the reduction of incidence and prevalence of HIV among adolescent girls and young women, women of childbearing age, and adult men, an additional 3.5 million babies were born HIV-free from 2004 to 2021. Now, 5.5 million babies have been born HIV-free as a result of PEPFAR and its partners.

At least 12 high HIV disease burden countries have reached the UNAIDS 90/90/90 HIV treatment targets

PEPFAR has supported at least 12 high HIV disease burden countries to reach the UNAIDS 90/90/90 HIV treatment targets, advancing global progress toward the UN Sustainable Development Goal target of ending the AIDS epidemic as a public health threat by 2030. The COVID pandemic and other threats make these gains fragile. Results from 2021 **Botswana's Population Health Impact Assessment demonstrates exceptional population-level impact at 95/98/98.**

Nearly 20 million women, men, and children are on life-saving antiretroviral treatment

As of March 31, 2022, PEPFAR supported life-saving antiretroviral treatment for nearly 20 million men, women, and children (compared with 17.2 million in FY20).

2 million clients newly enrolled on PrEP to prevent HIV infection since FY20

As of March 31, 2022, 680,000 individuals have newly enrolled on antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection. Demand for PrEP continues to increase, with 1 million people receiving PrEP in FY21 and 312,000 in FY20.

Lessons from COVID-19 and HIV

PEPFAR has continued to save and improve lives through swift and decisive action, country policy adaptation, agility, and innovation. This included:

- Expansion of decentralized distribution and **multi-month dispensing of life-saving antiretroviral medications by 480%**, essential to have clients stay in care and reduce their exposure to COVID-19.
- **Scale up of self-testing by 200%** since FY19 with 4.3 million people using HIV self-tests in FY21.
- **Increased use of digitalization** of the COVID-19 response, with data systems, technologies, and innovation that are critical to the HIV response.

Increasing Investments in Vulnerable Populations

PEPFAR is increasing its investment to close known gaps in services among key populations, adolescent girls and young women, and children, increasing its planned investment from FY 22 in these populations by nearly 15%, 20%, and 30%, respectively for FY 23 (pending Congressional Notification).

